Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non
Adoptive T cell therapy primarily includes three modalities: TILs, TCR-T, and CAR-T therapies. TIL therapy involves the ex vivo expansion of tumor-reactive T cells isolated after tumor resection, enhancing T cell infiltration and cytotoxicity against solid tumors with a generally favorable safety pr...
the PreVent-ACaLL trial (clinicaltrials.gov: NCT03868722). This trial investigates whether three months of acalabrutinib and venetoclax combination targeted treatment can improve the grade ≥3 infection-free, treatment-free
High dose Bortezomib plus second line chemo-therapy in treatment of patients with fractory and relapsed diffuse large B cell lymphoma,West China Hospital of Sichuan University,Observational,Not Applicable
388 2 of 11 role of isoquinoline-type alkaloids in cancer therapy [8,9], such as berberine targeted inhibition of prostate cancer [10], tetrandrine with significant anti-proliferation activity against hepatoma cells [11], and berbamine effectively inhibiting leukemia [12], lymphoma [13], myeloma...